Previous 10 | Next 10 |
Gainers: vTv Therapeutics (VTVT) +22%, Forte Biosciences (FBRX) +20%, Penumbra (PEN) +14%, Cellect Biotechnology (APOP) +10%, Inari Medical (NARI) +10%.Losers: Tricida (TCDA) -52%, Cancer Genetics (CGIX) -34%., Constellation Pharmaceutica...
Tricida (TCDA) plummets 46% after announcing an update on its End-of-Review Type A meeting with the FDA. This meeting followed a Complete Response Letter ((CRL)) received by the company in August 2020, for the veverimer NDA that was under FDA review through the Accelerated Approval ...
Cancer Genetics (CGIX) -38% after upsized public offering.Tricida (TCDA) -29% after updating its end-of-review Type A meeting with the FDA.Miragen Therapeutics (MGEN) -15%.Nokia (NOK) -16% after Q3 earnings results.CPS Technologies (CPSH) -14% after Q3 earni...
Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced to...
Presentations Focus on the Implications of Metabolic Acidosis and CKD Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polyme...
Tricida suffers setback on Veverimer front Tricida Inc. ( TCDA ) reported that the FDA has given a Complete Response Letter to the company for its application pertaining to Veverimer. The New Drug Application for the drug candidate was being reviewed under the Accelerated Approval Progra...
Gainers: Cancer Genetics (NASDAQ: CGIX ) +142% . More news on: Cancer Genetics, Inc., iBio, Inc., Sonnet BioTherapeutics Holdings, Inc., Stocks on the move, , Read more ...
Tricida ( TCDA -14.5% ) has received a Complete Response Letter (CRL) from the FDA regarding its marketing application seeking approval of veverimer (TRC101) for metabolic acidosis in patients with chronic kidney disease (CKD). More news on: Tricida, Inc., Healthcare stocks news, ...
Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today th...
CureVac (NASDAQ: CVAC ) +47% on making reasonable profit on COVID-19 vaccine. More news on: CureVac N.V., LMP Automotive Holdings, Inc., Microbot Medical Inc., Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Penny Stocks Under $1 It’s another choppy session in the stock market today, but penny stocks remain a shining light for day traders. Despite the S&P, Nasdaq, and Dow taking a hiatus from a two-day recession-fueled sell-off, traders are getting back in the saddle in preparation for...